|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Following a broad panel of immunohistochemical stains, the strong positive staining of the spindle cells for LCA (CD45), CD20, and Bcl-6 confirmed the diagnosis of follicle center cell lymphoma.
|
31693188 |
2020 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus BCL6 is considered to be involved in germinal center (GC)-derived lymphoma.
|
31063496 |
2019 |
|
Adult Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We identified 122 patients diagnosed as having large B-cell lymphoma (44, MYC-negative; 29, MYC-EC; 23, MYC rearrangement; 22, MYC and BCL2 rearrangements; 4, MYC, BCL2, and BCL6 rearrangements). p53 expression significantly correlated with DLBCL with abnormal MYC status (MYC-EC, MYC rearrangement, and MYC overexpression), but adverse p53 prognostic effect was only seen with MYC-rearranged lymphoma.
|
30496802 |
2019 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our studies identify PRMT5 as a novel regulator of the GC reaction and highlight the mechanistic rationale of cotargeting PRMT5 and BCL6 in lymphoma.
|
30082494 |
2018 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Simple karyotyping revealed key translocations involving MYC, BCL2, and BCL6 that have impacted lymphoma classification in the World Health Organization classification scheme.
|
30213388 |
2018 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
BCL6 as a therapeutic target for lymphoma.
|
29262721 |
2018 |
|
Adult Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here we show that the murine lymphoma cell line A20 resembles primary GCB cells in expression of GC-specific surface markers and the master transcription factor BCL6 and may serve as a useful system to model certain GCB cell behaviors in vitro.
|
29154209 |
2018 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma.
|
27717585 |
2017 |
|
Adult Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Hypermethylation of the Bcl6 locus followed by BCL6 upregulation was thought to be the key event for lymphoma development in mice.
|
27921272 |
2017 |
|
Adult Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There were 47 DTHLs, 36 cases with MYC and BCL2 and/or BCL6 extra signals (ES) and/or rearrangements (ES group, excludes DTHLs), 9 with MYC rearrangements only (single-hit lymphoma), and 95 with no MYC abnormalities (NM).
|
28614202 |
2017 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein we show that the actions of EZH2 in driving GC formation and lymphoma precursor lesions require site-specific binding by the BCL6 transcriptional repressor and the presence of a non-canonical PRC1-BCOR-CBX8 complex.
|
27505670 |
2016 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However BCL6 also directly represses several DLBCL oncogenes such as BCL2 and BCL-XL that promote lymphoma survival.
|
26657288 |
2016 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrate the usefulness of synthetic lethal screening of a conditionally BCL6-deficient Burkitt lymphoma cell line, DG75-AB7, with a library of small molecules to determine survival pathways suppressed by BCL6 and suggest mechanism-based treatments for lymphoma.
|
27268052 |
2016 |
|
Adult Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Patients with both MYC and BCL2 CNA had similar outcomes to those with classic double hit lymphoma or protein double expression lymphoma (MYC and BCL2/BCL6 coexpression).
|
26158410 |
2015 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A significant association was seen between lymphoma stage and BCL6 (p=0.045) but not MUM1 expression (p=0.09).
|
25640395 |
2015 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data confirm ITM2B as a target of BCL6 repression in lymphoma.
|
25557390 |
2015 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, we summarize recent advances on BCL6 mechanisms of action and the deregulation of its target gene networks in lymphoma.
|
24698494 |
2014 |
|
Adult Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BCL6 is overexpressed in the majority of patients with aggressive diffuse large B-cell lymphoma (DLBCL), the most common lymphoma in adulthood, and transgenic mice constitutively expressing BCL6 in B cells develop DLBCLs similar to the human disease.
|
22113614 |
2012 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We speculate that the poor outcome of primary adrenal lymphoma might be related to the bulky tumor size at presentation, non-germinal center B-cell phenotype, and frequent BCL-6 gene rearrangement.
|
19525926 |
2009 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
They were subclassified using CD10, mum-1, bcl-6 as germinal center B-cell like (GCB) lymphoma (30%) and non-GCB lymphoma (70%).
|
19298719 |
2009 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Seven cases of triple-hit lymphoma/leukemia (dual-hit lymphoma/leukemia with 3q27/BCL6 translocation) were included; the median survival of these patients was only 4 months from the diagnosis of the dual-hit lymphoma/leukemia.
|
19535347 |
2009 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, tandem targeting of the overlapping BCL6 and p53 transcriptional programs can correct aberrant survival pathways in DLBCL and might provide an effective therapeutic approach to lymphoma therapy.
|
18451163 |
2008 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several experiments and mouse models mimicking BCL6 translocation occurring in human lymphoma have demonstrated the oncogenic role of BCL6 and constitute a rational to consider BCL6 as a new therapeutic target in NHL.
|
16815642 |
2007 |
|
Adult Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Highly discriminative expression profiles were produced on both simulated gene expression data and expression data from breast cancer and lymphoma datasets on the basis of ER and BCL-6 expression, respectively.
|
17963508 |
2007 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Reasoning that disruption of POZ domain-mediated interactions may be an effective route to antagonizing the effects of BCL-6 in lymphoma, we screened a library for peptide aptamers that specifically bind to BCL-6 POZ and not the POZ domains of related proteins and describe here the first of these reagents, Apt48.
|
16331266 |
2006 |